Johnson & Johnson recently lost another...

...legal battle to protect its blockbuster prostate cancer drug, Zytiga, from generic competition. Zytiga holds preferred tier status for 15% of all covered lives, which grows to 51% including prior authorization or step therapy. The company will now ask the U.S. Supreme Court for an injunction, but other manufactures may start developing generics as early as next year. 

SOURCE: MMIT Analytics, as of 11/28/18